| The Gardens Of Bellaire | |
| 4620 Bellaire Blvd, Bellaire, Texas 77401 | |
| (713) 665-3888 | |
| Name | The Gardens Of Bellaire |
|---|---|
| Location | 4620 Bellaire Blvd, Bellaire, Texas |
| Certified By | Medicare |
| No. of Certified Beds | 46 |
| Occupancy Rate | 58.26% |
| Medicare ID (CCN) | 455975 |
| Legal Business Name | Snh Se Tenant Trs, Inc. |
| Ownership Type | For Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Young men with lower testosterone levels throughout puberty become more sensitive to how the hormone influences the brain's responses to faces in adulthood, according to new research published in JNeurosci.
Most of the roughly 15.5 million cancer survivors in the U.S. receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
The study revealed that a variant of a protein involved in HIV pathogenesis can suppress production of an HIV protein, known as Nef. Nef is required for the human immunodeficiency virus to develop into AIDS through a series of complex events involving viral elements and cellular proteins. Nef has never been a target for drug treatment in HIV patients.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 17.07 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.44 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 42.86 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 9.8 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.26 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 0 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.5 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.23 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.09 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 4.35 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 29.27 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.49 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 64.61 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.88 | 82.93 |
News Archive
Young men with lower testosterone levels throughout puberty become more sensitive to how the hormone influences the brain's responses to faces in adulthood, according to new research published in JNeurosci.
Most of the roughly 15.5 million cancer survivors in the U.S. receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
The study revealed that a variant of a protein involved in HIV pathogenesis can suppress production of an HIV protein, known as Nef. Nef is required for the human immunodeficiency virus to develop into AIDS through a series of complex events involving viral elements and cellular proteins. Nef has never been a target for drug treatment in HIV patients.
› Verified 7 days ago